French medicines agency sanctions Novo Nordisk and Eli Lilly for obesity drug advertising

France's National Medicines Safety Agency has sanctioned Novo Nordisk and Eli Lilly for non-compliant advertising campaigns on obesity treatments.

Published 10sem1 sourceNotable

Lire en français

≈ 24sSpeed

The fact

Both companies exceeded legal limits for direct promotion to the public and healthcare professionals.

The ANSM is tightening control over drug advertising to prevent overuse or inappropriate prescriptions.

Click the link to read an article on the topic:

Le Monde

Explore this topic

France ANSM Novo Nordisk Eli Lilly #ANSM #antiobésité #publicité #régulation

What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.

FranceWorld map →

Follow topic →

Auto-synthesis from 1 media source · identified on May 8, 2026

← Back to home

The fact

Read more

Anti-obesity drugs: Novo Nordisk and Eli Lilly ads penalized

France: Novo Nordisk and Eli Lilly fined for illegal advertising

Novo Nordisk and Eli Lilly sanctioned for obesity drug misuse

Anti-obesity drugs: Novo Nordisk and Eli Lilly sanctioned for deceptive practices

Novo Nordisk and Eli Lilly wage ad war in the United States

Novo Nordisk sues Eli Lilly over misleading obesity treatment advertising